Clearside Biomedical presents data at ARVO 2023

Clearside Biomedical announced that several key poster presentations were delivered on the Company’s suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology, ARVO, 2023 Annual Meeting. Title: Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients with Persistent Activity Following Anti-VEGF Therapy: Participants in the study had persistent, active disease and were heavily treatment experienced anti-VEGF sub-responders. CLS-AX administered via suprachoroidal injection for was safe and well-tolerated in all cohorts. The Extension Study in cohorts 3 and 4, exhibited early signs of durability and reduction in treatment burden with participants experiencing a 77% – 85% reduction in treatment burden. Importantly, a post hoc analysis of CLS-AX also showed a biologic effect at higher doses with stable best corrected visual acuity and central subfield thickness. Title: Suprachoroidal delivery of CLS-301, a potent small molecule integrin antagonist, offers multimonth durability and high bioavailability in the chorioretina Summary: The purpose of the study was to assess safety, durability and compartmentalization of a suprachoroidally administered small molecule suspension of a potent integrin antagonist in a preclinical model. In the study, SCS delivery of an integrin inhibitor was well tolerated and offered targeted, compartmentalized, and durable drug delivery to the chorioretina. This trend is consistent with other small molecule suspensions injected into the SCS. Title: Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey Summary: The poster described retina/uveitis specialists who had completed at least 10 suprachoroidal injections of XIPERE and participated in virtual meetings in which they responded to 37 survey questions probing their experience. The findings from the survey of early adopters of XIPERE suggest suprachoroidal injection was easy to learn and patient improvements in vision and macular edema aligned with findings in clinical registration trials.